C91.32 Prolymphocytic leukemia of B-cell type, in relapse

Name of the Condition

• Prolymphocytic leukemia of B-cell type, in relapse
• ICD-10 Code: C91.32

Summary

Prolymphocytic leukemia of B-cell type (B-PLL) is a rare, aggressive form of chronic lymphoid leukemia characterized by the uncontrolled proliferation of mature B lymphocytes. In relapse, the disease has reappeared after a period of remission, indicating active disease progression. B-PLL primarily affects the blood, bone marrow, and lymphoid tissues, leading to high white blood cell counts and organ infiltration. Its aggressive nature often results in poor response to standard therapies, requiring prompt intervention to manage symptoms and disease control.

Causes

The exact cause of B-PLL is not fully understood, but it involves genetic mutations in B lymphocytes that disrupt normal cell regulation. Contributing factors may include environmental exposures, genetic predispositions, and alterations in immune system function. The condition is distinguished by the accumulation of prolymphocytes—larger, more immature-appearing cells than those seen in chronic lymphocytic leukemia (CLL)—which drive its aggressive behavior. Relapse may occur due to residual disease or treatment resistance.

Risk Factors

• Increasing age (most common in adults over 60)
• Prior history of CLL or other lymphoid malignancies
• Certain genetic abnormalities (e.g., translocations involving chromosome 14)
• Exposure to chemotherapy or radiation (less clearly established)
• Inadequate response to initial treatment

Symptoms

• Rapid onset of fatigue and weakness
• Fever or night sweats
• Unexplained weight loss
• Frequent infections
• Easy bruising or bleeding
• Swollen lymph nodes, liver, or spleen
• Bone or joint pain

Diagnosis

Diagnosis involves a physical examination, followed by blood tests to assess cell counts and identify abnormal lymphocytes. A bone marrow biopsy is typically performed to confirm the presence of prolymphocytes and assess disease activity. Flow cytometry or immunophenotyping may be used to characterize the B-cell population. Imaging studies (e.g., CT scans) may evaluate organ involvement. Relapse is confirmed by detecting disease recurrence after a period of remission.

Treatment Options

Treatment focuses on controlling disease progression and managing symptoms. Options may include targeted therapies (e.g., B-cell receptor inhibitors), chemotherapy, or immunotherapy. Stem cell transplantation may be considered for eligible patients. Supportive care, such as blood transfusions or infection management, is often necessary. Treatment plans are individualized based on patient health and disease characteristics.

Prognosis and Follow-Up

Prognosis for B-PLL in relapse is generally poor due to its aggressive nature and limited treatment responses. Regular follow-up is essential to monitor disease activity, manage complications, and adjust treatment. Survival rates vary, but relapse indicates a higher risk of progression. Ongoing surveillance helps detect recurrence early and guide therapeutic decisions.

Complications

• Severe infections due to impaired immune function
• Anemia, thrombocytopenia, or leukostasis from high white blood cell counts
• Organ damage from lymphoid infiltration (e.g., liver, spleen)
• Treatment-related toxicities (e.g., chemotherapy side effects)
• Increased risk of secondary malignancies

Lifestyle & Prevention

• Maintain a balanced diet to support overall health
• Practice good hygiene to reduce infection risk
• Avoid known environmental toxins (e.g., benzene)
• Follow medical advice for managing treatment side effects
• Stay up-to-date with vaccinations (as recommended by a healthcare provider)

When to Seek Professional Help

Seek immediate medical attention if you experience:

• Sudden worsening of fatigue or weakness
• High fever or unexplained chills
• Severe bleeding or bruising
• Difficulty breathing or chest pain
• New or worsening swollen lymph nodes, liver, or spleen
• Persistent bone or joint pain

Tips for Medical Coders

Use C91.32 for cases of prolymphocytic leukemia of B-cell type confirmed to be in relapse. Document the relapse status clearly, including clinical evidence (e.g., lab results, imaging) and prior treatment history. Ensure differentiation from other B-cell leukemias (e.g., CLL) and confirm the relapse phase to avoid miscoding. Follow clinical documentation guidelines for accuracy.